Anti-HIV therapy: Current and future directions

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 2031-2055

  Agrawal, Lokesh ^a,b   Lu, Xihua ^a   Jin, Qingwen ^a   Alkhatib, Ghalib ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CCR5; CXCR4; Fusion; HAART; HIV AIDS; Integrase; Protease; Reverse transcriptase

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR DIPIVOXIL; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOZIVUDINE TIDOXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RITROVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; T 1249; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ASTHENIA; BLOOD DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; DYSPEPSIA; FATIGUE; FATTY LIVER; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPARATHYROIDISM; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSOMNIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; MACULOPAPULAR RASH; MOUTH ULCER; MUSCLE DISEASE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RHINITIS; SKIN DISCOLORATION; SOMNOLENCE; STOMATITIS; VOMITING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; CYTOKINES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33744765246     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442100     Document Type: Review

References (307)

1. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003; 9(7): 839-43.
2. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9(7): 867-73.
3. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17(15): 2227-36.
4. Pomerantz RJ. HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. Am Fam Physician 1999; 59(10): 2855.
5. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-767.
6. Cocchi F, De Vico AL, Garzinodemo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8(+) T cells. Science 1995; 270: 1811-1815.
7. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
8. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272(5270): 1955-8.
9. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85(7): 1135-48.
10. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. Nature 1996; 381(6584): 661-6.
11. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion co-factors. Cell 1996; 85(7): 1149-58.
12. Dragic T, Litwin V, Allaway GP, Martin SR, Huang YX, Nagashima, KA, et al. HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
13. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86(3): 367-77.
14. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [see comments]. Nature 1996; 382(6593): 722-5.
15. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.[In Process Citation]. Immunol Rev 2000; 177: 99-111.
16. Salahuddin SZ, Markham PD, Popovic M, Sarngadharan MG, Orndorff S, Fladagar A, et al. Isolation of infectious human T-cell leukemia/ lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources. Proc Natl Acad Sci USA 1985; 82(16): 5530-4.
17. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71.
18. De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol 2004; 36(9): 1800-22.
19. Ezzell C. AZT given the green light for clinical treatment of AIDS. Nature 1987; 326(6112): 430.
20. Richman DD. HIV chemotherapy. Nature 2001; 410(6831): 995-1001.
21. Girard PM, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, et al. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000; 23(3): 227-35.
22. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995; 38(14): 2491-517.
23. Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, et al. (-)2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36(4): 733-9.
24. van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995; 171(5): 1166-71.
25. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124(12): 1086-8.
26. + cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995; 333(25): 1662-9.
27. McKinney RE, Jr., Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998; 133(4): 500-8.
28. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37(6): 1390-2.
29. Griffith BP, Brett-Smith H, Kim G, Mellors JW, Chacko TM, Garner RB, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 1996; 173(5): 1252-5.
30. 3. J Acquir Immune Defic Syndr 1999; 22(1): 39-48.
31. Eron JJ, Jr., Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14(11): 1601-10.
32. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170(5): 1157-64.
33. Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J, Jr., Stool E, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997; 126(5): 355-63.
34. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996; 173(2): 355-64.
35. Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1998; 129(7): 525-31.
36. Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, et al. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. Pediatrics 1999; 103(5): e62.
37. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003; 32(3): 255-8.
38. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292(2): 180-9.
39. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004; 18(17): 2269-76.
40. Richman DD. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am J Med 1990; 88(5B): 8S-10S.
41. Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, et al. The National Cancer Institute phase I study of 2′, 3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990; 12 Suppl 5: S522-33.
42. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NI-AID AIDS Clinical Trials Group. N Engl J Med 1992; 327(9): 581-7.
43. Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, et al. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Ann Intern Med 1995; 123(8): 561-71.
44. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997; 336(24): 1704-12.
45. Gallant JE, Pham PA. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection. Expert Rev Anti Infect Ther 2003; 1(3): 415-22.
46. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr 2003; 33(1): 15-21.
47. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, et al. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 1998; 37(41): 14394-403.
48. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research 1998; 38(3): 153-179.
49. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354(9181): 795-802.
50. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999; 354(9181): 803-9.
51. Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, et al. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antivir Ther 2003; 8(6): 595-602.
52. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7(2): 81-90.
53. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14(7): 807-12.
54. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998; 87(3): 306-10.
55. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16(9):595-609.
56. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39(12): 2602-5.
57. Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, de Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001; 27(5): 459-62.
58. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341(25): 1865-73.
59. Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001; 184(1): 37-42.
60. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345(6): 398-407.
61. Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2001; 183(3): 392-400.
62. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999; 341(25): 1874-81.
63. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4(5): 437-46.
64. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997; 71(4): 3023-30.
65. Balzarini J, Hatse S, Vermeire K, Princen Y, Aquaro S, Perno CF, et al. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 2004; 48(10): 3858-70.
66. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004: 48(1): 337-9.
67. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000; 275(19): 14316-20.
68. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48(12): 4680-6.
69. Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. Aids 2003; 17(18): 2623-7.
70. Venaud S, Yahi N, Fehrentz JL, Guettari N, Nisato D, Hirsch I, et al. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication. Res Virol 1992; 143(5): 311-9.
71. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. Aids 2001; 15(1): F1-9.
72. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44(8): 2093-9.
73. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44(9): 2319-26.
74. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. Aids 2003, 17(9): 1339-49.
75. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile]. MMW Fortschr Med 2004; 146 Spec No 1: 90.
76. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18(16): 2137-44.
77. Nadler J, A Rodriguez-French, J Millard, P Wannamaker. The NEAT Study: GW433908 Efficacy and Safety in ART-naïve Subjects, Final 48-week Analysis. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA, USA; 2003.
78. DeJesus E, A LaMarca, M Sension, C Beltran, P Yeni. The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA, USA; 2003.
79. Macmanus S, P.Yates, S. White, N. Richards, W. Snowden. GW433908 in ART-naive Subjects: Absence of Resistance at 48 Weeks with Boosted Regimen and APV-like Resistance Profile with Unboosted Regimen. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA, USA; 2003.
80. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333(7): 401-7.
81. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51(RR-7): 1-55.
82. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277(5322): 112-6.
83. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351(9117): 1682-6.
84. Daniel N, Schneider V, Pialoux G, Krivine A, Grabar S, Nguyen TH, et al. Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. Aids 2003, 17(14): 2126-9.
85. Carr A, Samaras K, Thorisdottir A, Kaufmann GF, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353(9170): 2093-9.
86. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13(18): 2493-505.
87. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15(9): 1181-3.
88. Dornadula G, Nunnari G, Vanella M, Roman J, Babinchak T, De-Simone J, et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001, 183(11): 1682-7.
89. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula, G, Zhang H, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186(10): 1403-11.
90. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003; 349(24): 2293-2303.
91. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, et al. Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003; 349(24): 2304-2315.
92. Ananworanich J, Hirschel B. Interrupting highly active antiretroviral therapy in patients with HIV. Expert Rev Anti Infect Ther 2005; 3(1): 51-60.
93. Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, et al. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 2003; 17(16): 2337-43.
94. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349(9): 837-46.
95. Katlama sd, claudine duvivier, constance delaugerre, gilles peytavin, mayeule legrand, vincent calvez, karine gourlain, dominique costagliola. Long-term Benefit of Treatment Interruption in Salvage Therapy (GIGHAART ANRS 097). In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA; 2003.
96. Izopet J, Souyris C, Sandres-Saune K, Puissant B, Obadia M, Pasquier C, et al. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. J Med Virol 2002; 68(3): 305-10.
97. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34(4): 407-14.
98. Trout H, Mentre F, Panhard X, Kodjo A, Escaut L, Pernet P, et al. Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004; 48(2): 538-45.
99. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-93.
100. Pomerantz RJ. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis 2002; 34(1): 91-7.
101. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629): 183-8.
102. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54(1): 6-9.
103. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280(5371): 1866-7.
104. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387(6629): 188-91.
105. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5(5): 512-7.
106. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 1996; 174(2): 404-7.
107. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276(5314): 960-4.
108. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94(23): 12574-9.
109. Kotler DP. Intestinal disease associated with HIV infection: characterization and response to antiretroviral therapy. Pathobiology 1998; 66(3-4): 183-8.
110. Ellis CM, Suckling J, Amaro E Jr, Bullmore ET, Simmons A, Williams SC, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57(9): 1571-8.
111. Moir S, Lapointe R, Malaspina A, Ostrowski M, Cole CE, Chun TW, et al. CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J Virol 1999; 73(10): 7972-80.
112. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312: 767-768.
113. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74(5): 667-75.
114. Otto MJ. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4(5): 431-6.
115. Furman PA, Jeffrey J, Kiefer LL, Feng JY, Anderson KS, Borroto-Esoda K, et al. Mechanism of action of 1-beta-D-2, 6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother 2001; 45(1): 158-65.
116. Jeffrey JL, Feng JY, Qi CC, Anderson KS, Furman PA. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. J Biol Chem 2003; 278(21): 18971-9.
117. Pommier Y, Marchand C, Neamati N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res 2000; 47(3): 139-48.
118. King PJ, Robinson WE, Jr. Resistance to the anti-human immunodefieciency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998; 72(10):8420-4.
119. Robinson WE, Jr., Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase. Proc Natl Acad Sci USA 1996; 93(13): 6326-31.
120. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287(5453): 646-50.
121. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4(2): 206-9.
122. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Des 2003; 9(22): 1789-802.
123. Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77(21): 11459-70.
124. Daelemans D, Vandamme AM, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir Chem Chemother 1999; 10(1): 1-14.
125. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, et al. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 1997; 41(6): 1250-5.
126. Turpin JA, Buckheit RW, Jr., Derse D, Hollingshead M, Williamson K, Palamone C, et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother 1998; 42(3): 487-94.
127. Kashanchi F, Sadaie MR, Brady JN. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology 1997; 227(2): 431-8.
128. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997; 94(8): 3548-53.
129. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000; 57(1): 116-24.
130. Hoglund S, Ofverstedt LG, Nilsson A, Lundquist P, Gelderblom H, Ozel M, et al. Spatial visualization of the maturing HIV-1 core and its linkage to the envelope. AIDS Res Hum Retroviruses 1992; 8(1): 1-7.
131. Li S, Hill CP, Sundquist WI, Finch JT. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 2000; 407(6802): 409-13.
132. Fields BN, D. M. Knipe, and P. M. Howley Ed, Fields virology. 3rd ed. Philadelphia, Lippincott-Raven Publishers 1996.
133. Hoglund S, Su J, Reneby SS, Vegvari A, Hjerten S, Sintorn IM, et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother 2002; 46(11): 3597-605.
134. Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, et al. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob Agents Chemother 2002; 46(5): 1394-401.
135. Furman PA, Davis M, Liotta, DC, Paff M, Frick LW, Nelson DJ, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36(12): 2686-92.
136. Wakeford C, G. Shen, L. Hulett, J.B. Quinn, F. Rousseau. Long-term Efficacy and Safety of Emtricitabine in HIV+ Adults Switching from a Lamivudine Containing HAART Regimen. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA; 2003.
137. Borkow G, Arion D, Wainberg MA, Parniak MA. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43(2): 259-63.
138. Balzarini J, Naesens L, Verbeken E, Laga, M, Van Damme L, Parniak M, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998; 12(10): 1129-38.
139. Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D, et al. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999; 104(4): R1-5.
140. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999; 247(25): 17478-83.
141. Wishka DG, Graber DR, Kopta LA, Olmsted RA, Friis JM, Hosley JD, et al. (-)6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J Med Chem 1998; 41(9): 1357-60
142. Currens MJ, Gulakowski RJ, Mariner JM, Moran RA, Buckheit RW, Jr., Gustafson KR, et al. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996; 279(2): 645-51.
143. Buckheit RW, Jr., White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999; 43(8): 1827-34.
144. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, et al. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001; 45(5): 1379-86.
145. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998; 352(9123): 199-200.
146. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999; 15(7): 619-24.
147. Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999; 180(6): 1827-32.
148. Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, Greenberg RN, et al. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res 2002; 56(2): 167-81.
149. Balter M. AIDS research. Cytokines move from the margins into the spotlight. Science 1995; 268(5208): 205-6.
150. Hall SS. IL-12 holds promise against cancer, glimmer of AIDS hope. Science 1994; 263(5154): 1685-6.
151. Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, et al. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates; Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 2004; 92(3): 957-64.
152. Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J Infect Dis 2000; 182(4): 1070-6.
153. Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, et al. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059. J Acquir Immune Defic Syndr 2002; 29(3): 221-31.
154. Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, et al. Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci USA 2002; 99(16): 10712-7.
155. Pido-Lopez J, Burton C, Hardy G, Pires A, Sullivan A, Gazzard B, et al. Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune). AIDS Res Hum Retroviruses 2003; 19(2): 103-9.
156. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzler J, et al. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003; 187(2): 320-5.
157. Paredes R, Lopez Benaldo de Quiros JC, Fernandez-Cruz E, Clotet B, Lane HC. The potential role of interleukin-2 in patients with HIV infection. AIDS Rev 2002; 4(1): 36-40.
158. Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185(1): 61-8.
159. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
160. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1 [letter]. Nature 1998; 391(6664): 240.
161. Alkhatib G, Berger EA, Murphy PM, Pease JE. Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. Journal of Biological Chemistry 1997; 272(33): 20420-6.
162. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. Journal of Virology 1997; 71(12): 8999-9007.
163. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185(11): 2015-23.
164. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses [see comments]. Nature 1997; 388(6639): 296-300.
165. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, et al. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol 1998; 72(7): 6113-8.
166. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998; 72(10): 7934-40.
167. Simmons G, Reeves JD, Hibbitts S, Stine JT, Gray PW, Proudfoot AE, et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. [In Process Citation]. Immunol Rev 2000; 177: 112-26.
168. Lukacs NW, Tekkanat KK. Role of chemokines in asthmatic airway inflammation. [In Process Citation]. Immunol Rev 2000; 177: 21-30.
169. Baggiolini M. Reflections on chemokines. [In Process Citation]. Immunol Rev 2000, 177: 5-7.
170. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997; 234(2): 340-8.
171. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, et al. Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 1996; 274(5294): 1924-6.
172. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997; 186(1): 139-46.
173. Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, Goldsmith MA, et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proceedings of the National Academy of Sciences of the United States of America 1997; 94(10): 5061-6.
174. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382(6594): 833-5.
175. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382(6594): 829-33.
176. Signoret N, Oldridge J, Pelchen-Matthews A, Klasse PJ, Tran T, Brass LF, et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997; 139(3): 651-64.
177. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997; 11 (Suppl A): S3-S16.
178. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines [see comments]. Science 1996; 274(5287): 602-5.
179. Ugolini S, Moulard M, Mondor I, Barois N, Demandolx D, Hoxie J, et al. HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. J Immunol 1997; 159(6): 3000-8.
180. Xiao X, Wu L, Stantchev TS, Feng YR, Ugolini S, Chen H, et al. Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci USA 1999; 96(13): 7496-501.
181. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72(4): 2855-64.
182. Kuhmann SE, Platt EJ, Kozak SL, Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000; 74(15): 7005-15.
183. Dimitrov DS, Norwood D, Stantchev TS, Feng Y, Xiao X, Broder CC. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Virology 1999; 259(1): 1-6.
184. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384(6605): 179-83.
185. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co- receptor CCR-5. Nature 1996; 384(6605): 184-7.
186. Polo S, Nardese V, De Santis C, Arcelloni C, Paroni R, Sironi F, et al. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur J Immunol 2000; 30(11): 3190-8.
187. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, et al. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997; 186(10): 1793-8.
188. Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 1997; 94(12): 6426-31.
189. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, et al. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996; 87(3): 437-46.
190. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998; 72(1): 279-85.
191. Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 1997; 71(7): 5003-11.
192. Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004; 103(4): 1211-7.
193. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study [see comments] [published erratum appears in Science 1996 Nov 15;274(5290):10691. Science 1996; 273(5283): 1856-62.
194. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al, The role of a mutant CCR5 allele in HIV-1 transmission and disease progression [see comments]. Nat Med 1996; 2(11): 1240-3.
195. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3(1): 23-36.
196. Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, et al. Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004; 78(5): 2277-87.
197. Delwart EL, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses 1990; 6(6): 703-6.
198. Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989; 5(4): 431-40.
199. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995; 69(6): 3771-7.
200. Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR, Jr., Merutka G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996; 35(42): 13697-708.
201. Matthews TJ, Wild C, Chen CH, Bolognesi DP, Greenberg ML. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol Rev 1994; 140: 93-104.
202. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995; 11(3): 323-5.
203. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9(11): 1051-3.
204. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992; 89(21): 10537-41.
205. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89(2): 263-73.
206. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94(23): 12303-8.
207. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387(6631): 426-30.
208. Dubay JW, Roberts SJ, Brody B, Hunter E. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol 1992; 66(8): 4748-56.
209. Wild C, Dubay JW, Greenwell T, Baird T, Jr., Oas TG, McDanal C, et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994; 91(26): 12676-80.
210. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4(11): 1302-7.
211. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 2003; 57(10): 890-7.
212. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18(10): 685-93.
213. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17(5): 691-8.
214. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348(22): 2175-85.
215. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348(22): 2186-95.
216. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46(6): 1896-905.
217. Miralles G, JP Lalezari, N Bellos, G Richmond, Y Zhang, H Murchison, et al. T-1249 Demonstrates Potent Antiviral Activity over 10 Day Dosing in Most Patients who Have Failed a Regimen Containing Enfuvirtide (ENF): Planned Interim Analysis of T1249-102, a Phase I/II Study. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA; 2003.
218. Feinberg J. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage. AIDS Clin Care 2003; 15(11): 95-6.
219. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11(5): 533-9.
220. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990; 87(17): 6574-8.
221. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182(1): 326-9.
222. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183(7): 1121-5.
223. Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 2000; 182(6): 1774-9.
224. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1. J Infect Dis 2004; 189(2): 286-91.
225. Agrawal L, Alkhatib G. Chemokine receptors: emerging opportunities for new anti-HIV therapies. Expert Opin Ther Targets 2001; 5(3): 303-326.
226. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96(10): 5698-703.
227. Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, et al. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother 2001; 45(12): 3538-43.
228. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000; 97(10): 5639-44.
229. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000; 43(10): 2049-63.
230. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al. SCHC (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98(22): 12718-23.
231. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99(1): 395-400.
232. Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses 2003; 19(3): 177-86.
233. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77(9): 5201-8.
234. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46(5): 1336-9.
235. Este JA. Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs 2002; 3(3): 379-83.
236. Schurmann D, R Rouzier, R Nougarede, J Reynes, G Fatkenheuer, F Raffi, et al. SCH D: Antiviral Activity of a CCR5 Receptor Antagonist. In: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA; 2004.
237. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75(2): 579-88.
238. Olson WC, Burton DR. Fusion Inhibitor PRO 140 reduces HIV burden in mouse model. In: 14th International Conference on Antiviral Research; 2001; Seattle, Washington; 2001.
239. Franti M, K. Nagashima, P. Maddon, D. Burton, W. Osoln, and P. Poignard. The CCR5 Co-Receptor Inhibitor PRO 140 Effectively Controls Established infections in vivo. In: 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA; 2002.
240. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276(5310): 276-9.
241. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998; 187(8): 1215-24.
242. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73(5): 3544-50.
243. Elsner J, Mack M, Bruhl H, Dulkys Y, Kimmig D, Simmons G, et al. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000; 275(11): 7787-94.
244. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996; 271(5): 2599-603.
245. Princen K, Hatse S, Vermeire K, Bridger GJ, Skerlj RT, De Clercq E, et al. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level. AIDS Res Hum Retroviruses 2003; 19(12): 1135-9.
246. Hatse S, Princen K, Vermeire K, Gerlach LO, Rosenkilde MM, Schwartz TW, et al. Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett 2003;546(2-3):300-6.
247. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992; 89(12): 5286-90.
248. Schols D, Este JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997; 35(3): 147-56.
249. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co- receptor. Nat Med 1998; 4(1): 72-7.
250. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998; 72(8): 6381-8.
251. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996; 40(3): 750-4.
252. De Vreese K, Reymen D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, et al. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res 1996; 29(2-3): 209-19.
253. de Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996; 70(2): 689-96.
254. De Vreese K, Van Nerum I, Vermeire K, Anne J, De Clercq E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob Agents Chemother 1997; 41(12): 2616-20.
255. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999; 73(7): 5577-85.
256. Bridger GJ, Skerlj RT, Padmanabhan S, Martellucci SA, Henson GW, Struyf S, et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J Med Chem 1999; 42(19): 3971-81.
257. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR- 4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44(6): 1667-73.
258. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996, 40(3): 750-4.
259. Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem 2004; 4(9): 883-93.
260. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186(8): 1395-400.
261. Zhou N, Fang J, Acheampong E, Mukhtar M, Pomerantz RJ. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology 2003; 312(1): 196-203.
262. Luo Z, Zhou N, Luo J, Hall JW, Huang Z. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. Biochem Biophys Res Commun 1999, 263(3): 691-5.
263. Doranz BJ, Filion LG, Diaz-Mitoma F, Sitar DS, Sahai J, Baribaud F, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 2001; 17(6): 475-86.
264. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277(5332): 1656-9.
265. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines [see comments]. Science 1997; 278(5336): 290-4.
266. Dore GJ, Grulich A, Law MG, Brew BJ, Kaldor JM. Kaposi's sarcoma and protection from AIDS dementia complex. AIDS 1998; 12(17): 2354-5.
267. Liestael K, Goplen AK, Dunlop O, Bruun JN, Maehlen J. Kaposi's sarcoma and protection from HIV dementia [letter; comment]. Science 1998; 280(5362): 361-2.
268. Hibbitts S, Reeves JD, Simmons G, Gray PW, Epstein LG, Schols D, et al. Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. AIDS Res Hum Retroviruses 1999; 15(11): 989-1000.
269. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors pro 542 and t-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183(7): 1121-5.
270. Olson WC, Thompson DA, Nagashima KA. Potent, synergistic inhibition of HIV-1 by combination of the viral entry inhibitors PRO 542, PRO 140, and T-20. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada, 2000.
271. Tremblay CL, Kollmann C, Giguel F, C. CT, Hirsch MS. In vitro synergy observed between the fusion inhibitors T-20 and a CCR5 inhibitor TAK-779. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada; 2000.
272. Picchio G, Sabbe R, Neal Nea. Coreceptor trap therapy: combination of CCR5 and CXCR4 inhibitors blocks human immunodeficiency virus type 1 infection in vivo. In: 8th Conference on Retroviruses and Opportunistic Infections; 2001 February 4-8; Chicago, Illinois; 2001.
273. MacFarland R, Yasuda N, Witvrouw M. An orally bioavailable CXCR4 antagonist for inhibition of HIV replication. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada; 2000.
274. Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescue V, McDermott D, et al. Role for CCR5D32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J. Virol. 2004, 78(5): 2277-2287.
275. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA, 3rd, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001; 107(4): 431-8.
276. Schols D, Este JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998; 72(5): 4032-7.
277. Trkola A, Gordon C, Matthews J, Maxwell E, Ketas T, Czaplewski L, et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 1999; 73(8): 6370-9.
278. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, et al. CC-chemokines enhance the replication of T-tropic stains of HIV-1 in CD4(+) T cells: role of signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1998; 95(20): 11880-5.
279. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393(6685): 595-9.
280. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393(6685): 591-4.
281. Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998, 160(8): 4018-25.
282. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(9): 5215-20.
283. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med 2004; 10(3): 221-3.
284. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345(6276): 622-5.
285. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992, 355(6362): 728-30.
286. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, et al. Long-term protection of chimpanzees against highdose HIV-1 challenge induced by immunization. Nat Med 1997; 3(6): 651-8.
287. Girard M, Meignier B, Barre-Sinoussi F, Kieny MP, Matthews T, Muchmore E, et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995; 69(10): 6239-48.
288. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422(6929): 307-12.
289. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100(7): 4144-9.
290. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, et al. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 2000; 74(11): 5091-100.
291. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000; 74(2): 627-43.
292. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002; 76(17): 8875-89.
293. Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002; 76(15): 7760-76.
294. Olson WC, Ketas TJ, Nagashima KA. Potent, broad-spectrum inhibition of HIV-1 by the CCR5 antibody PRO 140. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 September 17-20, 2000; Toronto, Ontario, Canada; 2000.
295. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Research & Human Retroviruses 1995; 11(5): 533-9.
296. Yang OO, Swanberg SL, Lu Z, Dziejman M, McCoy J, Luster AD, et al. Enhanced inhibition of human immunodeficiency virus type 1 by Met- stromal-derived factor 1beta correlates with down-modulation of CXCR4. J Virol 1999; 73(6): 4582-9.
297. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999; 73(9): 7489-96.
298. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997, 186(8): 1389-93.
299. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998; 253(3): 877-82.
300. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73(2): 1719-23.
301. Tamamura H, Imai M, Ishihara T, Masuda M, Funakoshi H, Oyake H, et al. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5, 12), Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 1998; 6(7): 1033-41.
302. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186(8): 1383-8.
303. Van Gelder J, Witvrouw M, Pannecouque C, Henson G, Bridger G, Naesens L, et al. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. Int J Pharm 1999; 186(2): 127-36.
304. Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B, et al. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface- expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob Agents Chemother 2000; 44(1): 51-6.
305. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10(3): 315-36.
306. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004; 10(32): 4039-53.
307. Pereira CF, Paridaen JT. Anti-HIV drug development-an overview. Curr Pharm Des 2004; 10(32): 4005-37.